Parveen K Garg1, Weihua Guan2, Sarah Nomura3, Natalie Weir3, Amy B Karger3, Daniel Duprez4, Susan R Heckbert5, Michael Y Tsai3. 1. Division of Cardiology, University of Southern California, Los Angeles, CA, USA. 2. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 3. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. 4. Division of Cardiology, University of Minnesota, Minneapolis, MN, USA. 5. Department of Epidemiology, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Current literature examining the prospective relation of circulating omega-3 (n-3) and omega-6 (n-6) PUFAs and atrial fibrillation (AF) is limited to predominantly white populations. OBJECTIVES: We investigated the association of circulating n-3 and n-6 PUFAs with incident AF in participants from the Multi-Ethnic Study of Atherosclerosis. METHODS: A total of 6229 participants (mean age = 62 y; 53% female; 39% white, 27% black, 22% Hispanic, and 12% Chinese) who were free of baseline AF and with plasma phospholipid PUFAs measured at baseline using GC were prospectively followed for the development of AF. Incident AF was ascertained using International Classification of Diseases-9 codes from hospital discharge records and Medicare claims data with follow-up through 2014. Multivariable Cox proportional hazards regression analysis was performed to determine the risk of incident AF. RESULTS: During a median follow-up of 12.9 y, 813 (13%) participants developed AF. Each higher SD increment in arachidonic acid (AA; 20:4n-6) concentrations was associated with an 11% decreased risk of incident AF (HR: 0.89; 95% CI: 0.82, 0.96). Similarly, higher overall n-6 PUFA concentrations were also associated with a reduced AF risk (HR per SD increment: 0.93; 95% CI: 0.87, 1.00). Although no significant overall associations were observed for any individual n-3 PUFAs, higher circulating concentrations of DHA (22:6n-3) and EPA (20:5n-3) were associated with a decreased AF risk in blacks and Hispanics (DHA only) but not whites or Chinese Americans. CONCLUSIONS: In a multiethnic cohort of individuals free of baseline cardiovascular disease, higher plasma concentrations of n-6 PUFAs, particularly AA, were associated with a reduced risk of incident AF. Important differences in AF risk were also noted across race/ethnicity for the n-3 PUFAs DHA and EPA.
BACKGROUND: Current literature examining the prospective relation of circulating omega-3 (n-3) and omega-6 (n-6) PUFAs and atrial fibrillation (AF) is limited to predominantly white populations. OBJECTIVES: We investigated the association of circulating n-3 and n-6 PUFAs with incident AF in participants from the Multi-Ethnic Study of Atherosclerosis. METHODS: A total of 6229 participants (mean age = 62 y; 53% female; 39% white, 27% black, 22% Hispanic, and 12% Chinese) who were free of baseline AF and with plasma phospholipid PUFAs measured at baseline using GC were prospectively followed for the development of AF. Incident AF was ascertained using International Classification of Diseases-9 codes from hospital discharge records and Medicare claims data with follow-up through 2014. Multivariable Cox proportional hazards regression analysis was performed to determine the risk of incident AF. RESULTS: During a median follow-up of 12.9 y, 813 (13%) participants developed AF. Each higher SD increment in arachidonic acid (AA; 20:4n-6) concentrations was associated with an 11% decreased risk of incident AF (HR: 0.89; 95% CI: 0.82, 0.96). Similarly, higher overall n-6 PUFA concentrations were also associated with a reduced AF risk (HR per SD increment: 0.93; 95% CI: 0.87, 1.00). Although no significant overall associations were observed for any individual n-3 PUFAs, higher circulating concentrations of DHA (22:6n-3) and EPA (20:5n-3) were associated with a decreased AF risk in blacks and Hispanics (DHA only) but not whites or Chinese Americans. CONCLUSIONS: In a multiethnic cohort of individuals free of baseline cardiovascular disease, higher plasma concentrations of n-6 PUFAs, particularly AA, were associated with a reduced risk of incident AF. Important differences in AF risk were also noted across race/ethnicity for the n-3 PUFAs DHA and EPA.
Authors: Jason H Y Wu; Rozenn N Lemaitre; Irena B King; Xiaoling Song; Frank M Sacks; Eric B Rimm; Susan R Heckbert; David S Siscovick; Dariush Mozaffarian Journal: Circulation Date: 2012-01-26 Impact factor: 29.690
Authors: Rachel R Huxley; Faye L Lopez; Aaron R Folsom; Sunil K Agarwal; Laura R Loehr; Elsayed Z Soliman; Rich Maclehose; Suma Konety; Alvaro Alonso Journal: Circulation Date: 2011-03-28 Impact factor: 29.690
Authors: Nahed Hussein; Eric Ah-Sing; Paul Wilkinson; Clare Leach; Bruce A Griffin; D Joe Millward Journal: J Lipid Res Date: 2004-12-01 Impact factor: 5.922
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Gerald V Naccarelli; Deborah L Wolbrette; Soraya Samii; Javier E Banchs; Erica Penny-Peterson; Mario D Gonzalez Journal: Expert Rev Cardiovasc Ther Date: 2007-07
Authors: Rozenn N Lemaitre; Toshiko Tanaka; Weihong Tang; Ani Manichaikul; Millennia Foy; Edmond K Kabagambe; Jennifer A Nettleton; Irena B King; Lu-Chen Weng; Sayanti Bhattacharya; Stefania Bandinelli; Joshua C Bis; Stephen S Rich; David R Jacobs; Antonio Cherubini; Barbara McKnight; Shuang Liang; Xiangjun Gu; Kenneth Rice; Cathy C Laurie; Thomas Lumley; Brian L Browning; Bruce M Psaty; Yii-Der I Chen; Yechiel Friedlander; Luc Djousse; Jason H Y Wu; David S Siscovick; André G Uitterlinden; Donna K Arnett; Luigi Ferrucci; Myriam Fornage; Michael Y Tsai; Dariush Mozaffarian; Lyn M Steffen Journal: PLoS Genet Date: 2011-07-28 Impact factor: 5.917
Authors: Tagreed A Mazi; Kamil Borkowski; Oliver Fiehn; Christopher L Bowlus; Souvik Sarkar; Karen Matsukuma; Mohamed R Ali; Dorothy A Kieffer; Yu-Jui Y Wan; Kimber L Stanhope; Peter J Havel; John W Newman; Valentina Medici Journal: Metabolites Date: 2022-02-19
Authors: Behnam Tajik; Tomi-Pekka Tuomainen; Masoud Isanejad; Jukka T Salonen; Jyrki K Virtanen Journal: Eur J Nutr Date: 2021-12-27 Impact factor: 4.865